

Access to Kidney Cancer Treatments in the UK – 24 August 2018

Page 1 of 2

DRUG: Trade (generic) name Manufacturer	INDICATION	STATUS
Sutent (sunitinib) Pfizer	First-line treatment for metastatic RCC	Available on the NHS
Votrient (pazopanib) Novartis	First-line treatment for metastatic RCC	Available on the NHS
Fotivda (tivozanib) Aveo/Eusa	First-line treatment for metastatic RCC	Available on the NHS in England and Wales only
Opdivo (nivolumab) BMS	Second/third-line treatment for advanced/metastatic RCC	Available on the NHS
Afinitor (everolimus) Novartis	Second/third-line treatment for advanced RCC	2 nd line - Available on the NHS in England, Scotland and Wales only 3 rd line – Available on the NHS in Wales
Inlyta (axitinib) Pfizer	Second-line treatment for advanced RCC	Available on the NHS
Cabometyx (cabozantinib) Ipsern	Second-line treatment for metastatic RCC	Available on the NHS
Cabometyx (cabozantinib) Ipsern	First-line treatment for locally advanced/metastatic RCC	Available on the NHS in England and Wales only
Kisplyx (lenvatinib) in combination with Afinitor (everolimus) Eisai, Novartis	Second-line treatment for advanced RCC	Available on the NHS in England, Wales and Northern Ireland only
Intron A/Roferon A (interferon alpha)	Advanced/metastatic RCC	Available on the NHS
Proleukin (aldesleukin/IL2) High dose interleukin 2	Advanced/metastatic RCC	Available to pre-selected patients only at specialist research sites (Christie Hospital, Manchester and Barts Cancer Institute, London). Not funded by the NHS

Access to Kidney Cancer Treatments in the UK – 24 August 2018

Page 2 of 2

DRUG: Trade (generic) name Manufacturer	INDICATION	STATUS
Torisel (temsirolimus) <i>Pfizer</i>	First-line treatment for advanced RCC of poor prognosis	Not routinely available on the NHS Access via individual funding request*
Avastin (bevacizumab) <i>Roche</i>	First-line treatment for advanced/metastatic RCC in combination with interferon alpha	Not routinely available on the NHS Access via individual funding request*
Nexavar (sorafenib) <i>Bayer</i>	First/second-line treatment for advanced/metastatic RCC	Not routinely available on the NHS Access via individual funding request*
Cabometyx (cabozantinib) <i>Ipsen</i>	First-line treatment for locally advanced/metastatic RCC	Undergoing SMC appraisal
Opdivo (nivolumab) in combination with Yervoy (ipilimumab) <i>BMS</i>	First-line treatment for metastatic RCC	Undergoing NICE appraisal
Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) <i>Roche</i>	First-line treatment for locally advanced/metastatic RCC	Undergoing NICE appraisal
Prolia (denosumab) <i>Amgen</i>	Cancer that has spread to the bones as an alternative to bisphosphonates	Available on the NHS

Clinical Trials for Kidney Cancer - Please go to our clinical trials database for a complete list of all clinical trials for kidney cancer in the UK:

<http://www.kcsn.org.uk/clinical-trials-hub/clinical-trials-database/>

*Individual funding requests may be submitted via the following route:

- England and Northern Ireland: Individual Funding Request (IFR)
- Wales: Individual Patient Funding Request (IPFR)
- Scotland: Individual Patient Treatment Request (IPTR)